Knight Therapeutics Inc.
KHTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.91 | 0.85 | 0.07 | -0.91 |
| FCF Yield | 0.95% | 4.71% | 2.48% | -27.43% |
| EV / EBITDA | 7.35 | 13.75 | 23.64 | 14.31 |
| Quality | ||||
| ROIC | 1.79% | -0.26% | -0.17% | -1.36% |
| Gross Margin | 46.97% | 46.51% | 47.03% | 47.40% |
| Cash Conversion Ratio | 8.37 | -2.13 | -1.35 | 2.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.15% | 10.47% | 13.74% | 72.47% |
| Free Cash Flow Growth | -81.49% | 77.16% | 108.17% | -446.24% |
| Safety | ||||
| Net Debt / EBITDA | -0.48 | 0.25 | 0.24 | -1.06 |
| Interest Coverage | 0.80 | -0.23 | -0.36 | -1.47 |
| Efficiency | ||||
| Inventory Turnover | 1.92 | 1.91 | 1.68 | 1.77 |
| Cash Conversion Cycle | 156.75 | 112.12 | 86.12 | 121.26 |